InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,185.33
(
-0.05%
)
US TECH 100
17,619.80
(
0.04%
)
Dow Jones
38,971.28
(
0.22%
)
Brent Oil
83.33
(
0.56%
)
Bitcoin
61,999.97
(
-0.54%
)
Post# of 251751
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

stockbettor

Send PM Follow Ignore
Followers 3
Posts 278
Boards Moderated 0
Alias Born 03/08/2008

stockbettor

Re: DewDiligence post# 196383

Monday, 10/26/2015 9:15:36 AM

Monday, October 26, 2015 9:15:36 AM

Post# of 251751

1) Patients with Child-Pugh-B (or even more advanced) cirrhosis who were prescribed V-Pak even though the FDA label did not recommended V-Pak for such patients


As noted a year ago, data from the TURQUOISE-2 trial showed a beneficial impact of V-Pak on the liver function of patients with cirrhosis. Be interesting to find out if there is any real world confirmation of that trial data in patients with less severe cirrhosis who have been treated with V-Pak.

http://investorshub.advfn.com/boards/replies.aspx?msg=107364913
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up